VELCADE (bortezomib), proteasome inhibitor

• This focus concerns only the Marketing Authorisation indications of VELCADE in the treatment of relapsed myeloma, i.e. in patients who have already undergone or who are ineligible for a haematopoietic stem cell transplant.

It is indicated in second-line as monotherapy or in combination with dexamethasone or CAELYX.

It is also indicated in third-line as monotherapy.

• The available data and lack of comparative data versus the recommended alternatives (including REVLIMID in combination with dexamethasone) do not demonstrate a clinical benefit in the current therapeutic strategy for relapsed multiple myeloma.
• Its place in monotherapy or in combination with dexamethasone is restricted, particularly in monotherapy for patients who have received at least two prior treatments.
• According to experts, its combination with CAELYX has no place in the therapeutic strategy of relapsed multiple myeloma having received at least one line of treatment.